Agenus Inc.
AGEN Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
AGEN Income Statement
AGEN Balance Sheet
AGEN Cash Flow
Recent trades of AGEN by members of U.S. Congress
AGEN Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
AGEN Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
AGEN Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by AGEN's directors and management
Government lobbying spending instances
-
$30,000 Apr 16, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Jan 22, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$30,000 Oct 16, 2023 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$10,000 Jul 20, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Jan 18, 2018 Issue: Medical/Disease Research/Clinical Labs
-
$10,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Jun. 18, 2024
-
Patent Title: Antibodies and methods of use thereof May. 28, 2024
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof May. 28, 2024
-
Patent Title: Anti-gitr antibodies and methods of use thereof Feb. 13, 2024
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Dec. 12, 2023
-
Patent Title: Anti-tigit and anti-cd96 antibodies Aug. 08, 2023
-
Patent Title: Anti-cd73 antibodies and methods of use thereof Jul. 04, 2023
-
Patent Title: Antibodies that specifically bind human cd96 Jun. 20, 2023
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 02, 2023
-
Patent Title: Methods of administering anti-ox40 antibodies Oct. 18, 2022
-
Patent Title: Antibodies and methods of use thereof Sep. 20, 2022
-
Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies Aug. 16, 2022
-
Patent Title: Anti-gitr antibodies and methods of use thereof Aug. 02, 2022
-
Patent Title: Anti-ox40 antibodies and anti-gitr antibodies Jun. 14, 2022
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof May. 31, 2022
-
Patent Title: Vectors comprising nucleic acids encoding anti-ox40 antibodies May. 17, 2022
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 08, 2022
-
Patent Title: Anti-cd137 antibodies and methods of use thereof Feb. 08, 2022
-
Patent Title: Anti-ox40 antibodies Oct. 05, 2021
-
Patent Title: Anti-cd137 antibodies and methods of use thereof Aug. 24, 2021
-
Patent Title: Heat shock protein-binding peptide compositions and methods of use thereof Jul. 20, 2021
-
Patent Title: Anti-tigit antibodies and methods of use thereof Jun. 01, 2021
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 25, 2021
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Feb. 09, 2021
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof Feb. 09, 2021
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 05, 2021
-
Patent Title: Anti-lag-3 antibodies and methods of use thereof Nov. 24, 2020
-
Patent Title: Antibodies and methods of use thereof Nov. 17, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Nov. 10, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Oct. 13, 2020
-
Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies May. 05, 2020
-
Patent Title: Anti-tim-3 antibodies and methods of use thereof May. 05, 2020
-
Patent Title: Anti-gitr antibodies and methods of use thereof Mar. 03, 2020
-
Patent Title: Vaccines for treatment and prevention of cancer Feb. 25, 2020
-
Patent Title: Identification of antigen- or ligand-specific binding proteins Dec. 10, 2019
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Nov. 19, 2019
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof Oct. 22, 2019
-
Patent Title: Anti-pd-1 antibodies and methods of use thereof Jun. 18, 2019
-
Patent Title: Anti-gitr antibodies and methods of use thereof May. 07, 2019
-
Patent Title: Anti-ox40 antibodies Apr. 16, 2019
-
Patent Title: Anti-gitr antibodies and methods of use thereof Dec. 18, 2018
-
Patent Title: Anti-ctla-4 antibodies and methods of use thereof Dec. 04, 2018
-
Patent Title: Cell surface display, screening and production of proteins of interest May. 09, 2017
-
Patent Title: Identification of antigen or ligand-specific binding proteins Mar. 14, 2017
-
Patent Title: Vaccine for treatment and prevention of herpes simplex virus infection Sep. 24, 2013
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of AGEN in WallStreetBets Daily Discussion
AGEN News
Recent insights relating to AGEN
CNBC Recommendations
Recent picks made for AGEN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AGEN
AGEN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AGEN Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More